Epygenix Advancing EPX-100 to Phase 2 Trial in Dravet Patients, Based on Positive Phase 1 Results
Epygenix Therapeutics is planning to launch a Phase 2 clinical trial testing EPX-100 in patients with Dravet syndrome, after Phase 1 results showed the investigational therapy was safe and well tolerated in healthy volunteers. EPX-100 is a repurposed antihistamine, originally known as clemizole, which was…